Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  GM2-KLH vaccine
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-8 of 8 for your search:
Start Over
Phase III Randomized Study of Vaccination with Ganglioside GM2 Conjugated to Key Hole Limpet Hemocyanin plus Immunologic Adjuvant QS21 vs High Dose Interferon Alfa-2b in Patients with High Risk Melanoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: E-1694, CAN-NCIC-ME9, MDA-DM-E1694, MSKCC-96008, SWOG-9512, CAN-NCIC-E1694, MSKCC-E1694, SWOG-E1694, E1694, ME9
Vaccine Therapy in Treating Patients With Primary Stage II Melanoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 80
Sponsor: Other
Protocol IDs: CDR0000067645, EORTC-18961, BMS-CA152-003, NCT00005052
Phase II Pilot Study of Booster Vaccinations with GM2-KLH plus QS21 for Stage III/IV Melanoma (Summary Last Modified 03/95)
Phase: Phase II
Type: Treatment
Status: Completed
Age: any age
Sponsor:
Protocol IDs: MSKCC-94009A1, NCI-V94-0458
Phase II Pilot Study of Vaccination with GM2-KLH plus QS21 in Stage III/IV Melanoma (Summary Last Modified 06/95)
Phase: Phase II
Type: Treatment
Status: Closed
Age: no age specified
Sponsor: NCI
Protocol IDs: MSKCC-94041, NCI-H94-0471
Phase I Study of GM2-KLH Vaccine Plus the Immunological Adjuvant QS21 for Prostate Cancer (Summary Last Modified 06/98)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-97097, NCI-G97-1340
Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 97-123, MSKCC-97123, NCI-H98-0015, NCT00003357
Start Over